BRAF V600E mutational status in pediatric thyroid cancer

Pediatric Blood and Cancer

Volumn 61, Issue 7, 2014, Pages 1168-1172

  Henke, Lauren E ^a   Perkins, Stephanie M ^a   Pfeifer, John D ^a   Ma, Changquing ^a   Chen, Yumei ^a   Dewees, Todd ^a   Grigsby, Perry W ^a,b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

BRAF mutation; BRAF V600E; Pediatric BRAF mutation; Pediatric thyroid carcinoma

Indexed keywords

B RAF KINASE; BRAF V600E PROTEIN; IODINE 131; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; CANCER THERAPY; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; CLINICAL FEATURE; FEMALE; FOLLOW UP; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MALE; MUTATIONAL ANALYSIS; NECK DISSECTION; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RETROSPECTIVE STUDY; SEX DIFFERENCE; THYROID CARCINOMA; THYROIDECTOMY; THYROTROPIN BLOOD LEVEL;

BRAF MUTATION; BRAF V600E; PEDIATRIC BRAF MUTATION; PEDIATRIC THYROID CARCINOMA;

ADOLESCENT; ADULT; AGE FACTORS; AMINO ACID SUBSTITUTION; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALE; MUTATION, MISSENSE; NEOPLASM INVASIVENESS; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PROTO-ONCOGENE PROTEINS B-RAF; RETROSPECTIVE STUDIES; SEX FACTORS; SURVIVAL RATE; THYROID NEOPLASMS;

EID: 84899697026     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24935     Document Type: Article

References (33)

1. McClellan DR, Francis GL. Thyroid cancer in children, pregnant women, and patients with Graves' disease. Endocrinol Metab Clin North Am 1996; 25:27-48.
2. Hogan AR, Zhuge Y, Perez EA, et al. Pediatric thyroid carcinoma: Incidence and outcomes in 1753 patients. J Surg Res 2009; 156:167-172.
3. Holmes L, Hossain J, Opara F. Pediatric thyroid carcinoma incidence and temporal trends in the USA (1973-2007): Race or shifting diagnostic paradigm? ISRN Oncol 2012; 2012:1-10.
4. Neiva F, Mesquita J, Paco Lima S, et al. Thyroid carcinoma in children and adolescents: A retrospective review. Endocrinol Nutr 2012; 59:105-108.
5. O'Gorman CS, Hamilton J, Rachmiel M, et al. Thyroid cancer in childhood: A retrospective review of childhood course. Thyroid 2010; 20:375-380.
6. Kiratli PO, Volkan-Salanci B, Günay EC, et al. Thyroid cancer in pediatric age group: An institutional experience and review of the literature. J Pediatr Hematol Oncol 2013; 35:93-97.
7. Rivkees SA, Mazzaferri EL, Verburg FA, et al. The treatment of differentiated thyroid cancer in children: Emphasis on surgical approach and radioactive iodine therapy. Endocr Rev 2011; 32:798-826.
8. Grigsby PW, Gal-or A, Michalski JM, et al. Childhood and adolescent thyroid carcinoma. Cancer 2002; 95:724-729.
9. Demidchik YE, Demidchik EP, Reiners C, et al. Comprehensive clinical assessment of 740 cases of surgically treated thyroid cancer in children of Belarus. Ann Surg 2006; 243:525-532.
10. Zimmerman D, Hay ID, Gough IR, et al. Papillary thyroid carcinoma in children and adults: Long-term follow-up of 1039 patients conservatively treated at one institution during three decades. Surgery 1988; 104:1157.
11. Yamashita S, Saenko V. Mechanisms of disease: Molecular genetics of childhood thyroid cancers. Nat Clin Pract Endocrinol Metab 2007; 3:422-429.
12. Xing M. BRAF mutation in thyroid cancer. Endocr Relat Cancer 2005; 12:245-262.
13. Fagin JA, Mitsiades N. Molecular pathology of thyroid cancer: Diagnostic and clinical implications. Best Pract Res Clin Endocrinol Metab 2008; 22:955-969.
14. Elisei R, Ugolini C, Viola D, et al. BRAFV600E mutation and outcome of patients with papillary thyroid carcinoma: A 15-year median follow-up study. J Clin Endocrinol Metab 2008; 93:3943-3949.
15. Penko K, Livezey J, Fenton C, et al. BRAF mutations are uncommon in papillary thyroid cancer of young patients. Thyroid 2005; 15:320-325.
16. Kumagai A. Low frequency of BRAFT1796A mutations in childhood thyroid carcinomas. J Clin Endocrinol Metab 2004; 89:4280-4284.
17. Lima J. BRAF mutations are not a major event in post-chernobyl childhood thyroid carcinomas. J Clin Endocrinol Metab 2004; 89:4267-4271.
18. Suchy B, Waldmann V, Klugbauer S, et al. Absence of RAS and p53 mutations in thyroid carcinomas of children after Chernobyl in contrast to adult thyroid tumours. Br J Cancer 1998; 77:952-955.
19. Furlan JC, Bedard YC, Rosen IB. Role of fine-needle aspiration biopsy and frozen section in the management of papillary thyroid carcinoma subtypes. World J Surg 2004; 28:880-885.
20. Kurian EM, Dawlett M, Wang J, et al. The triage efficacy of fine needle aspiration biopsy for follicular variant of papillary thyroid carcinoma using the Bethesda reporting guidelines. Diagn Cytopathol 2011; 40:E69-E73.
21. Sujoy V, Pinto A, Nosé V. Columnar cell variant of papillary thyroid carcinoma: A study of 10 cases with emphasis on CDX2 expression. Thyroid 2013; 23:714-719.
22. Ghossein R, Livolsi VA. Papillary thyroid carcinoma tall cell variant. Thyroid 2008; 18:1179-1181.
23. Lee X, Gao M, Ji Y, et al. Analysis of differential BRAFV600E mutational status in high aggressive papillary thyroid microcarcinoma. Ann Surg Oncol 2008; 16:240-245.
24. Oler G, Ebina KN, Michaluart P, et al. Investigation of BRAF mutation in a series of papillary thyroid carcinoma and matched-lymph node metastasis reveals a new mutation in metastasis. Clin Endocrinol 2005; 62:509-511.
25. Park SY, Park YJ, Lee YJ, et al. Analysis of differential BRAFV600E mutational status in multifocal papillary thyroid carcinoma. Cancer 2006; 107:1831-1838.
26. Zatelli MC, Trasforini G, Leoni S, et al. BRAF V600E mutation analysis increases diagnostic accuracy for papillary thyroid carcinoma in fine-needle aspiration biopsies. Eur J Endocrinol 2009; 161:467-473.
27. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009; 19:1167-1214.
28. Silberstein EB, Alavi A, Balon HR, et al. The SNMMI Practice Guideline for Therapy of Thyroid Disease with 131I 3.0. J Nucl Med 2012; 53:1633-1651.
29. Kimura ET, Nikiforova MN, Zhu Z, et al. High prevalence of BRAF mutations in thyroid cancer: Genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 2003; 63:1454-1457.
30. Puxeddu E. BRAFV599E mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas. J Clin Endocrinol Metab 2004; 89:2414-2420.
31. Xu X, Quiros RM, Gattuso P, et al. High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. Cancer Res 2003; 63:4561-4567.
32. Gouveia C, Can NT, Bostrom A, et al. Lack of association of BRAF mutation with negative prognostic indicators in papillary thyroid carcinoma: The University of California, San Francisco, Experience. JAMA Otolaryngol Head Neck Surg 2013; 139:1164-1170.
33. Nikiforova MN, Ciampi R, Salvatore G, et al. Low prevalence of BRAF mutations in radiation-induced thyroid tumors in contrast to sporadic papillary carcinomas. Cancer Lett 2004; 209:1-6.